Cohort A for Pancreatic Cancer

NYU Langone Health, New York, NY
Pancreatic CancerEzabenlimab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial tests a new immunotherapy treatment for pancreatic cancer patients to see if it's safe and effective. Patients receive 3 separate treatments and will be compared to an observational group.

Eligible Conditions
  • Pancreatic Cancer

Treatment Effectiveness

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Throughout the study, on average 2.4 years

Year 4
Disease-free survival (DFS), defined as the time from randomization until confirmed relapse or death from any cause, whichever occurs earlier.
Month 5
Occurrence of dose-limiting toxicity (DLT)
Up to 12 months
Proportion of patients achieving ctDNA clearance
up to 12 months
Proportion of patients experiencing ctDNA non-progression

Trial Safety

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

4 Treatment Groups

Cohort C Observational
1 of 4
Cohort A
1 of 4
Cohort B
1 of 4
Cohort C Treatment
1 of 4

Active Control

Experimental Treatment

85 Total Participants · 4 Treatment Groups

Primary Treatment: Cohort A · No Placebo Group · Phase 1

Cohort AExperimental Group · 3 Interventions: ATP152, VSV-GP154, ATP150 · Intervention Types: Drug, Drug, Drug
Cohort BExperimental Group · 4 Interventions: Ezabenlimab, ATP152, VSV-GP154, ATP150 · Intervention Types: Drug, Drug, Drug, Drug
Cohort C TreatmentExperimental Group · 4 Interventions: Ezabenlimab, ATP152, VSV-GP154, ATP150 · Intervention Types: Drug, Drug, Drug, Drug
Cohort C ObservationalNoIntervention Group · 1 Intervention: Cohort C Observational · Intervention Types:

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: throughout the study, on average 2.4 years

Who is running the clinical trial?

Amal TherapeuticsLead Sponsor
1 Previous Clinical Trials
96 Total Patients Enrolled
Boehringer IngelheimIndustry Sponsor
2,419 Previous Clinical Trials
10,168,721 Total Patients Enrolled
Paul Oberstein, MDPrincipal InvestigatorNYU Langone Health
1 Previous Clinical Trials
30 Total Patients Enrolled
Shubham Pant, MDPrincipal InvestigatorM.D. Anderson Cancer Center
4 Previous Clinical Trials
199 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

What is the highest recorded enrolment of patients taking part in this trial?

"Affirmative, the details from clinicaltrials.gov verify that this trial is presently welcoming participants. It was initially made public on March 13th 2023 and has since undergone its most recent update on May 4th 2023. The research requires 85 people to enrol at 1 site." - Anonymous Online Contributor

Unverified Answer

Is there still a possibility to join this research project?

"Affirmative, the public information on clinicaltrials.gov states that this research project is recruiting participants at present. This trial was originally posted online in March 13th 2023 and last updated in May 4th 2023. The experiment requires 85 patients from one medical facility to take part." - Anonymous Online Contributor

Unverified Answer

Does Cohort A have the necessary regulatory clearance to be introduced into marketplaces?

"Our team has assigned Cohort A a safety score of 1, as it is currently in the preliminary stages of its clinical trials with limited evidence to back up efficacy and safety." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.